AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)
← catalyst calendarNCT07611110 · readout in 909 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · Single · Treatment
Enrollment
670estimated
Sites
104
Countries
Australia, Austria, Brazil +14
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-05-04 | actual | When the study began enrolling |
| Primary completion | 2029-02-13 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-12-20 | estimated | The whole study's end, after follow-up |
| First posted | 2026-05-28 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-01 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Metastatic Castration-resistant Prostate Cancer
Interventions
- Drug: AZD2265 — also filed as FPI-2265
- Drug: Cabazitaxel — also filed as Jevtana
- Drug: Abiraterone — also filed as Zytiga
- Drug: Enzalutamide — also filed as Xtandi
- Drug: Apalutamide — also filed as Erleada
- Drug: Darolutamide — also filed as Nubeqa
- Drug: Rezvilutamide — also filed as Ariane
- Drug: Radium-223 — also filed as Xofigo
Primary outcomes
what the primary-completion date above is the date OFRadiographic Progression-Free Survival (rPFS)
measured From randomization until first radiographic progression per RECIST 1.1/PCWG3 by BICR, or death from any cause, whichever occurs first (up to approximately 33 months)
Overall Survival (OS)
measured From randomization until death from any cause (up to approximately 33 months)
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed